Myelin and oligodendrocyte lineage cell dysfunctions: New players in the etiology and treatment of depression and stress‐related disorders. (20th December 2019)

• Record Type: Journal Article
• Authors: Boda, Enrica
• Other Names: Barrot Michel guestEditor.; Yalcin Ipek guestEditor.
• Is Part Of: European journal of neuroscience. Volume 53:Number 1(2021)
• Page Start: 281
• Page End: 297
• Publication Date: 2019-12-20
• Subjects: antidepressant -- early life experience -- myelination -- neuromodulation; Nervous system -- Periodicals; 612.8
• DOI: 10.1111/ejn.14621
• Languages: English
• ISSNs: 0953-816X

Abstract

Abstract: Depressive disorders are complex, multifactorial disorders that have been traditionally attributed exclusively to neuronal abnormalities. However, recent studies have increased our understanding of the contribution of glial cells—and particularly of oligodendroglia—to the pathogenesis and treatment outcome of depression and stress‐related disorders. This review scrutinizes recent studies focusing on the neurosupportive functions exerted by myelin and oligodendrocyte lineage cells and their disruption in depression and stress‐related disorders. It also illustrates how myelin and oligodendroglia respond to antidepressants and non‐pharmacological treatment alternatives and proposes oligodendroglia‐directed approaches as novel therapeutic options for depressive disorders. Abstract : Depressive disorders have been traditionally attributed exclusively to neuronal abnormalities. Recent studies have increased our understanding of the functions exerted by myelin and oligodendrocyte lineage cells and provided evidence of their contribution to the pathogenesis and treatment outcome of depression and stress‐related disorders. Myelin/oligodendrocyte lineage cells appear now as novel promising targets for the treatment for depressive disorders.